Free Trial
→ $0. Later: $29.97. (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$3.92
-2.0%		$4.47
$2.25
▼
$6.60
$621.75M0.962.22 million shs1.15 million shs
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$64.97
$64.81
$8.33
▼
$65.00
$4.46B0.971.92 million shsN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.21
-3.6%		$4.25
$3.10
▼
$9.12
$31.94M1.15130,967 shs64,372 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-7.83%+10.80%+15.27%-30.80%+65.98%
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
0.00%0.00%0.00%0.00%0.00%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-2.35%+0.91%-16.54%-35.71%-29.53%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$3.92
-2.0%		$4.47
$2.25
▼
$6.60
$621.75M0.962.22 million shs1.15 million shs
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$64.97
$64.81
$8.33
▼
$65.00
$4.46B0.971.92 million shsN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.21
-3.6%		$4.25
$3.10
▼
$9.12
$31.94M1.15130,967 shs64,372 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-7.83%+10.80%+15.27%-30.80%+65.98%
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
0.00%0.00%0.00%0.00%0.00%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-2.35%+0.91%-16.54%-35.71%-29.53%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
3.11
Buy$11.33189.12% Upside
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
0.00
N/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
2.33
Hold$33.00928.04% Upside

Current Analyst Ratings Breakdown

Latest ALPN, SCYX, and ACRS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/30/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$10.00 ➝ $13.00
10/28/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$9.00
10/28/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$10.00 ➝ $8.00
10/28/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$16.00
10/22/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/21/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/1/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$10.00
9/1/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$10.00
8/13/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$24.00 ➝ $33.00
(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$7.83M79.41N/AN/A$1.05 per share3.73
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$56.52M78.85N/AN/A$4.85 per share13.40
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$20.60M1.55N/AN/A$5.93 per share0.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$64.92M-$0.58N/AN/AN/A-1,244.09%-59.19%-42.19%N/A
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
-$32.18M-$0.64N/AN/AN/A-65.17%-14.86%-11.82%N/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$8.61M-$1.44N/AN/AN/AN/A-39.29%-30.45%N/A

Latest ALPN, SCYX, and ACRS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.16-$0.12+$0.04-$0.12$1.27 million$1.48 million
11/5/2026Q3 2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.72-$0.71+$0.01-$0.71$0.13 million$0.13 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/AN/AN/AN/AN/A
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/A
5.09
5.09
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/A
9.56
9.56
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
7.57
9.65

Institutional Ownership

CompanyInstitutional Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
98.34%
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
75.17%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%

Insider Ownership

CompanyInsider Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
4.80%
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
42.30%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
73158.61 million151.00 millionOptionable
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
14268.60 million39.58 millionNo Data
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
299.95 million9.55 millionOptionable

Recent News About These Companies

FY2026 EPS Forecast for SCYNEXIS Reduced by Analyst
November 12 at 1:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31192863
SCYNEXIS Targets Year-End Kidney Drug Trial as Antifungal Program Advances
November 10 at 4:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31190292
SCYNEXIS (NASDAQ:SCYX) Cut to "Sell" at Wall Street Zen
November 10 at 2:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31189009
SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/05/3396422/0/en/scynexis-reports-third-quarter-2026-financial-results-and-provides-corporate-update.html
SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
October 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/29/3391192/0/en/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference.html
SCYNEXIS: IV SCY-247 Shows Favorable Safety And Exposure In Phase 1 Study
October 22, 2026  |  rttnews.comhttps://www.rttnews.com/3701897/scynexis-iv-scy-247-shows-favorable-safety-and-exposure-in-phase-1-study.aspx
SCYNEXIS Secures Up To $214M In BARDA Support For SCY-247 Development; Stock Up
October 22, 2026  |  rttnews.comhttps://www.rttnews.com/3701900/scynexis-secures-up-to-214m-in-barda-support-for-scy-247-development-stock-up.aspx
SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
October 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386244/0/en/scynexis-completes-phase-1-study-of-intravenous-scy-247-a-novel-triterpenoid-antifungal-in-development-for-treatment-and-prevention-of-invasive-fungal-diseases.html
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
October 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385884/0/en/scynexis-to-feature-scy-247-in-a-pipeline-presentation-at-idweek.html
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease
October 7, 2026  |  marketscreener.comM
SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?
October 7, 2026  |  defenseworld.netD
SCYNEXIS Reports Favorable Phase 1 Results For ADPKD Drug
October 6, 2026  |  rttnews.comhttps://www.rttnews.com/3696850/scynexis-reports-favorable-phase-1-results-for-adpkd-drug.aspx
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease ...
October 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scynexis-announces-phase-1-study-results-for-scy-770-a-novel-highly-selective-oral-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-1036600549
SCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026
October 6, 2026  |  quiverquant.comQ
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375347/0/en/scynexis-announces-phase-1-study-results-for-scy-770-a-novel-highly-selective-oral-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd.html
SCYNEXIS Secures BARDA Funding for Antifungal Pipeline
September 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SCYX/pressreleases/4866303/scynexis-secures-barda-funding-for-antifungal-pipeline/
SCYNEXIS Secures BARDA Funding for Antifungal Pipeline
September 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SCYX/pressreleases/4866303/scynexis-secures-barda-funding-for-antifungal-pipeline/
Scynexis stock surges on $214M BARDA contract for SCY-247
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scynexis-stock-surges-214m-barda-135830821.html
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scynexis-shares-rise-13-9-121017917.html
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
September 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/28/3369788/0/en/scynexis-awarded-barda-contract-providing-up-to-214-million-in-non-dilutive-funding-for-the-development-of-scy-247.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aclaris Therapeutics stock logo

Aclaris Therapeutics NASDAQ:ACRS

$3.92 -0.08 (-2.00%)
Closing price 04:00 PM Eastern
Extended Trading
$3.92 0.00 (-0.13%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Alpine Immune Sciences stock logo

Alpine Immune Sciences NASDAQ:ALPN

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$3.21 -0.12 (-3.60%)
Closing price 04:00 PM Eastern
Extended Trading
$3.19 -0.02 (-0.62%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas